Skip to main content

TBC Moderna Australia Pty Ltd

Product name
Accepted date
Active ingredients
respiratory syncytial virus F protein mRNA (nucleoside modified)
Proposed indication
For the prevention of lower respiratory tract disease (LRTD) and acute respiratory disease (ARD) caused by respiratory syncytial virus (RSV).
Application type
A (new medicine)
Publication date
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available.

Help us improve the Therapeutic Goods Administration site